02211 UNI HEALTH
- 0.167
- +0.005+3.09%
UNI HEALTH News
China Post Securities released a research report on April 28 stating that it gave Guilin Sanjin (002275.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the first quarter was under short
Tianfeng Securities released a research report on April 28 stating that it gave Neusoft Group (600718.SH) a holding rating. The main reasons for the rating include: 1) comments: the company's performance turned losses into profits, and growth potential be
Pacific released a research report on April 24 stating that Baiya shares (003006.SZ) were given a purchase rating. The main reasons for the rating include: 1) the structural drive profit of major health products such as probiotics; 2) high marketing inves
Guojin Securities released a research report on April 22 stating that it gave Kangenbei (600572.SH) an increase in its holdings. The main reasons for the rating include: 1) product structure optimization, healthy growth in the core business of Traditional
Research Report Nuggets | Dongwu Securities: Yaben Chemical actively explores the pharmaceutical+health sector and maintains a “buy” rating
Research Report Nuggets | Dongwu Securities: Actively exploring the pharmaceutical+health sector, optimistic about the growth potential of Yaben Chemical, giving it the first “buy” rating
Morgan Stanley raised the target price of Jintian Pharmaceutical to 4.5 yuan
Morgan Stanley maintains the target price of 4.5 yuan for Jintian Pharmaceutical Group to increase its holding rating.
Research report of Jintian Medicine (2211.HK)
Jintian Medicine (2211.HK)
IPO report: Jintian Pharmaceutical Group Co., Ltd. (2211.HK)
No Data